Mitochondrial Long Non-Coding RNAs in Gynecological Cancers: Pathogenic Signaling Pathways and Therapeutic

Ioana-Stefania Bostan1,2, Nicolae Gica1,2, Mirela Mihaila3,4

  • 1Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050471 Bucharest, Romania.

Insights

Mitochondrial long non-coding RNAs (mt-lncRNAs) are emerging players in gynecological cancers, influencing tumor progression and treatment resistance. Understanding their role in mitochondrial-nuclear communication offers new therapeutic and diagnostic opportunities for ovarian, cervical, and endometrial cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gynecological cancers present significant challenges due to late-stage diagnosis and complex molecular drivers.
  • Nuclear long non-coding RNAs (lncRNAs) are implicated in tumor progression, metastasis, and therapy resistance in these cancers.
  • Mitochondrial dysfunction and lncRNAs are critical in tumor cell survival, metabolic adaptation, and stress response.

Purpose of the Study:

  • To review the regulatory mechanisms of mitochondrial lncRNAs in ovarian, cervical, and endometrial cancers.
  • To consolidate current knowledge on mitochondrial lncRNA functions in gynecological malignancies.
  • To identify novel research avenues and therapeutic targets.

Main Methods:

  • Literature review focusing on mitochondrial lncRNAs in gynecological cancers.
  • Analysis of molecular mechanisms involving mitochondrial lncRNAs.
  • Synthesis of data on mitochondrial-nuclear communication.

Main Results:

  • Nuclear lncRNAs modulate chromatin, microRNAs, and mitochondrial dynamics, promoting cancer progression.
  • Mitochondrial lncRNAs (mt-lncRNAs) are involved in retrograde signaling, respiration, and apoptosis regulation.
  • Dysregulated mt-lncRNAs impact tumor bioenergetics, mitochondrial integrity, and gene expression.

Conclusions:

  • Mitochondrial lncRNAs play a significant role in the development and progression of gynecological cancers.
  • Elucidating mt-lncRNA functions in mitochondrial-nuclear crosstalk can lead to new interventions.
  • mt-lncRNAs show potential as diagnostic biomarkers and therapeutic targets in gynecological oncology.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K